Molecular Targets in Protein Misfolding and Neurodegenerative Disease

Aimed at 'drug discoverers' - i.e. any scientist who is interested in neurodegenerative diseases in general, and in finding disease-modifying treatments in particular - the first edition of Molecular Targets in Protein Misfolding and Neurodegenerative Disease will contain both a detailed, discipline-specific coverage (paragraphs on medicinal chemistry, on clinical and preclinical characterization of compounds in development, on target identification and validation, on genetic factors influencing a pathology, etc.) and a drug discovery-oriented, overall evaluation of each target (validation, druggability, existing leads, etc.). Together these will satisfy the needs of various audiences, including in vitro biologists, pharmacologists, medicinal chemists, etc. - Written to provide a comprehensive coverage of disease-modifying mechanisms and compounds against neurodegenerative diseases - Provides a 'drug discovery application oriented perspective, evaluating targets and candidates for their overall therapeutic potential - Provides discipline-specific chapters (medicinal chemistry, target validation, preclinical and clinical development - Provides an overview on a number of molecular mechanisms (e.g. phosphorylation, chaperon refolding, ubiquitination, autophagy, microtubule transportation, protease cleavage, etc.) with relevance for any disease area - Contains a more thorough description of the therapeutic relevance of -10 specific molecular targets

Dr. Pierfausto Seneci is Associate Professor in the Department of Organic and Industrial Chemistry at the University of Milan. He is currently affiliated with the University of Milan Centre for Interdisciplinary Biomolecular Studies and Industrial Applications (CISI) Centre of Excellence, and is responsible for the Combinatorial Chemistry/High Throughput MedChem Laboratory. He has over 20 years of medicinal chemistry experience working in industry, and held business development positions with GSK, Sanofi, and start-up pharmaceutical companies including Sirenade and NiKem working in drug discovery, neurodegeneration, oncology, and antibacterials. He is author of approximately 80 papers on the topic and several book chapters, including the book 'Solid-Phase Synthesis and Combinatorial Technologies” with Wiley-Interscience in 2000.